Drugs / NXT007
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06189508 | Feb → Dec 2024 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05987449 | Sep 2023 → Dec 2033 expected | hemophilia A | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07416526 | May 2026 → Sep 2027 expected | hemophilia A | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07416604 | Apr 2026 → Feb 2028 expected | hemophilia A | Hoffmann-La Roche | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-23 | Roche Global Development | Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A roche.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXT007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06189508 ↗ |
| Route | Subcutaneous | “NXT007 administered subcutaneously (SC)” NCT05987449 ↗ |